Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
18.62
-1.38 (-6.90%)
Nov 20, 2024, 4:00 PM EST - Market open
Summit Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | - | - | 0.71 | 1.81 | 0.86 | 0.81 | Upgrade
|
| Revenue | - | - | 0.71 | 1.81 | 0.86 | 0.81 | Upgrade
|
| Revenue Growth (YoY) | - | - | -61.03% | 110.35% | 6.10% | -98.58% | Upgrade
|
| Gross Profit | - | - | 0.71 | 1.81 | 0.86 | 0.81 | Upgrade
|
| Selling, General & Admin | 57.67 | 30.27 | 26.74 | 23.61 | 19.23 | 12.3 | Upgrade
|
| Research & Development | 124.21 | 59.47 | 53.26 | 85.35 | 53.27 | 43.43 | Upgrade
|
| Other Operating Expenses | -0.29 | -1 | -14.42 | -20.97 | -19.31 | -24.95 | Upgrade
|
| Operating Expenses | 181.59 | 88.74 | 65.59 | 88 | 53.19 | 30.78 | Upgrade
|
| Operating Income | -181.59 | -88.74 | -64.89 | -86.19 | -52.33 | -29.97 | Upgrade
|
| Interest Expense | -11.57 | -16.46 | -4.4 | -0.24 | -0.26 | -0.32 | Upgrade
|
| Interest & Investment Income | 11.12 | 10.4 | 1.51 | - | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.48 | 1.03 | -4.11 | -2.14 | 0.05 | -1.45 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.11 | -0.25 | 0.3 | -0.04 | 0.48 | - | Upgrade
|
| EBT Excluding Unusual Items | -181.67 | -94.01 | -71.58 | -88.6 | -52.05 | -31.74 | Upgrade
|
| Asset Writedown | - | - | -8.47 | - | -0.86 | - | Upgrade
|
| Other Unusual Items | - | - | 1.27 | - | - | - | Upgrade
|
| Pretax Income | -196.68 | -614.93 | -78.78 | -88.6 | -52.91 | -31.74 | Upgrade
|
| Income Tax Expense | - | - | - | - | -0.21 | 0.04 | Upgrade
|
| Net Income | -196.68 | -614.93 | -78.78 | -88.6 | -52.7 | -31.77 | Upgrade
|
| Net Income to Common | -196.68 | -614.93 | -78.78 | -88.6 | -52.7 | -31.77 | Upgrade
|
| Shares Outstanding (Basic) | 709 | 620 | 193 | 92 | 70 | 33 | Upgrade
|
| Shares Outstanding (Diluted) | 709 | 620 | 193 | 92 | 70 | 33 | Upgrade
|
| Shares Change (YoY) | 28.70% | 220.50% | 109.60% | 32.67% | 111.78% | 90.55% | Upgrade
|
| EPS (Basic) | -0.28 | -0.99 | -0.41 | -0.96 | -0.76 | -0.97 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.99 | -0.41 | -0.96 | -0.76 | -0.97 | Upgrade
|
| Free Cash Flow | -113.02 | -76.89 | -42.21 | -72.89 | -48.53 | -22.87 | Upgrade
|
| Free Cash Flow Per Share | -0.16 | -0.12 | -0.22 | -0.79 | -0.70 | -0.70 | Upgrade
|
| Gross Margin | - | - | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | - | - | -9203.69% | -4764.29% | -6085.35% | -3697.58% | Upgrade
|
| Profit Margin | - | - | -11174.75% | -4897.84% | -6127.56% | -3920.19% | Upgrade
|
| Free Cash Flow Margin | - | - | -5986.67% | -4029.46% | -5643.26% | -2821.27% | Upgrade
|
| EBITDA | -181.49 | -88.54 | -63.62 | -84.84 | -50.78 | -28.56 | Upgrade
|
| D&A For EBITDA | 0.1 | 0.2 | 1.26 | 1.35 | 1.55 | 1.41 | Upgrade
|
| EBIT | -181.59 | -88.74 | -64.89 | -86.19 | -52.33 | -29.97 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.